Experimental vaccine combo takes on childhood brain cancer
NCT ID NCT04943848
First seen Mar 24, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This early-phase trial is testing a new vaccine (rHSC-DIPGVax) made from pieces of tumor proteins, given together with two immunotherapy drugs (balstilimab and zalifrelimab), in children with DIPG or diffuse midline glioma. The goal is to see if the combination is safe and tolerable. About 36 children who have completed radiation therapy will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ann and Robert H. Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Health Orange County (CHOC)
RECRUITINGOrange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Boston Children's Cancer and Blood Disorders Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rHSC-DIPGVax (a vaccine made from tumor protein fragments) combined with two immunotherapy drugs (balstilimab and zalifrelimab)
What this could lead to
If this works, it could point toward a new treatment option for children with DIPG and diffuse midline glioma, potentially helping the immune system fight these aggressive brain tumors.
What could go wrong
This is a very early, small phase 1 trial focused on safety, so it is unknown if the combination will actually shrink tumors or extend life. The treatments may cause serious immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.